Validation of the prediction score for inhibitor development in previously untreated patients (PUPs) with severe hemophilia A

被引：0
|
作者：
Hashemi, S. [1 ,2 ,3 ]
Fischer, K. [1 ,2 ]
Van den Berg, H. [3 ]
机构：
[1] UMC Utrecht, Dept Creveldklin & Hematol, Utrecht, Netherlands
[2] UMC Utrecht, Julius Ctr Hlth Sci, Utrecht, Netherlands
[3] UMC Utrecht, Dept Clin Chem & Haematol, Utrecht, Netherlands
来源：
HAEMOPHILIA | 2012年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：89 / 89
页数：1
相关论文
共 50 条
  • [21] Inhibitor development in relation to treatment duration in severe hemophilia A in previously untreated patients: results from the sippet trial
    Peyvandi, F.
    Mannucci, P. M.
    Garagiola, I
    Anzoletti, M. B.
    El-Beshlawy, A.
    El-Alfy, M.
    Madatha, V. R.
    Eshghi, P.
    Varadarajan, R.
    Hanagavadi, S.
    Karimi, M.
    Manglani, M., V
    Ross, C.
    Young, G.
    Seth, T.
    Apte, S.
    Nayak, D.
    Santagostino, E.
    Mancuso, E.
    Gonzalez, A. C. S.
    Owaidah, Tarek M.
    Rosendaal, F. R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 321 - 322
  • [22] Systematic Review of the Role of FVIII Concentrates in Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A: A 2013 Update
    Franchini, Massimo
    Coppola, Antonio
    Rocino, Angiola
    Santagostino, Elena
    Tagliaferri, Annarita
    Zanon, Ezio
    Morfini, Massimo
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2013, 39 (07): : 752 - 766
  • [23] Source and purity of factor VIII products as risk factors for inhibitor development in previously untreated patients with severe hemophilia A
    Mancuso, M.
    Mannucci, P.
    Rocino, A.
    Garagiola, I.
    Tagliaferri, A.
    Santagostino, E.
    HAEMOPHILIA, 2012, 18 : 87 - 87
  • [24] Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A
    Gouw, S. C.
    van den Berg, H. M.
    le Cessie, S.
    van der Bom, J. G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (07) : 1383 - 1390
  • [25] Source and Purity of Factor VIII Products As Risk Factors for Inhibitor Development In Previously Untreated Patients with Severe Hemophilia A
    Mancuso, Maria Elisa
    Mannucci, Pier Mannuccio
    Rocino, Angiola
    Garagiola, Isabella
    Tagliaferri, Annarita
    Santagostino, Elena
    BLOOD, 2011, 118 (21) : 15 - 16
  • [26] Prediction of inhibitor development in previously untreated and minimally treated children with severe and moderately severe hemophilia A using a machine-learning network
    Jardim, Leticia Lemos
    Schieber, Tiago A.
    Santana, Marcio Portugal
    Cerqueira, Monica Hermida
    Lorenzato, Claudia Santos
    Franco, Vivian Karla Brognoli
    Zuccherato, Luciana Werneck
    Santos, Brendon Ayala da Silva
    Chaves, Daniel Gonsalves
    Ravetti, Martin Gomez
    Rezende, Suely Meireles
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2024, 22 (09) : 2426 - 2437
  • [27] Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada
    Fischer, Kathelijn
    Lassila, Riitta
    Peyvandi, Flora
    Gatt, Alexander
    Hollingsworth, Rob
    Lambert, Thierry
    Kaczmarek, Radek
    Bettle, Amanda
    Samji, Nasrin
    Rivard, Georges-etienne
    Carcao, Manuel
    Iorio, Alfonso
    Makris, Mike
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (08)
  • [28] Economic analysis of an early prophylaxis regimen to reduce FVIII inhibitor development in previously untreated patients (PUPS) with severe haemophilia A
    Auerswald, G.
    Kurnik, K.
    Epstein, J. D.
    Crea, R.
    Reininger, A. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 825 - 825
  • [29] Kogenate treatment of previously untreated patients (PUPs) with hemophilia A: Update of safety, efficacy, and inhibitor development after seven study years.
    Lusher, J
    Arkin, S
    Abildgaard, CF
    Hurst, D
    BLOOD, 1996, 88 (10) : 1755 - 1755
  • [30] SAFETY, EFFICACY AND INHIBITOR RISK OF RECOMBINANT FACTOR-VIII (RECOMBINATE(R)) IN A COHORT OF PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH SEVERE HEMOPHILIA-A
    BRAY, GL
    COURTER, S
    LYNES, M
    LEE, M
    GOMPERTS, E
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 1205 - 1205
12345